This study aims to evaluate the efficacy and safety of picankibart for the treatment of moderately to severely active ulcerative colitis (modified Mayo score of 4 to 9 with an endoscopic subscore of ...

More than 6 million adults in the US live with plaque psoriasis, but it’s often a misunderstood disease. Joining the discussion is actress entrepreneur Lala Anthony and dermatologist Dr. Meghan ...

Though psoriasis affects people of all skin tones, that diversity isn’t always represented in portrayals of the condition in ...

The Food and Drug Administration (FDA) has approved Imuldosa ™ (ustekinumab-srlf), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Imuldosa, ...

At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...

Imuldosa is used for the treatment of patients with autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ...

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

“The heroes here tonight are not make-believe heroes from Marvel Comics, but real-life heroes who have made an impact on ...

In early October, La La Anthony revealed to her 15 million followers that she has been battling with plaque psoriasis.

FDA approves the biologics license application (BLA) that Dong-A submitted in 2023 for Imuldosa, a biosimilar referencing Stelara.